Tracers / [177Lu]Lu-PSMA-1-DOTA
[177Lu]Lu-PSMA-1-DOTA
Also written as [Lu-177]Lu-PSMA-1-DOTA
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- compassionate use
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting urea-based small molecule with DOTA chelator
- Target / mechanism
- PSMA (prostate-specific membrane antigen) targeting ligand PMID 40897948
- Clinical application
- PSMA-targeted radioligand therapy of prostate cancer PMID 40897948
- Theranostic pair
- <a href="/tracers/ga68-psma1dota/">ga68-psma1dota</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >95% | >94% | PSMA-1-DOTA | 40897948 2025 Mol Imaging Biol A stock solution of 177Lu (Eckert & Ziegler) in 0.04 M HCl was prepared in a clean reaction vial. — Typically, a crude yield of > 95% and a radiochemical purity > 94% were achieved. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-PSMA-1-DOTA, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40897948. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40897948: 'PSMA-1-DOTA'. Stage set/updated at stage 23 from PMID 40897948: 'A compassionate use PET imaging study on a patient with metastatic castration-resistant prostate cancer was performed using [68 Ga]Ga-PSMA-1-DOTA.'.